No Data
No Data
How strong are the Hong Kong pharmaceutical stocks right now? The Innovative Drugs Index has risen over 30% this year, reaching a near 16-month high.
① The Innovative Drugs Index in the Hong Kong stock market has increased by over 30% this year; why can it compete with Technology stocks? ② There has been a "small peak" in the commercialization of individual stocks; how do Institutions perceive the future market direction?
Is the CRO Concept "Return of the King"? WuXi AppTec aggressively attacks, leading stocks celebrate after performance!
Release the signal?!
Express News | The Concept of CRO fluctuated and strengthened, with WUXI APPTEC rising over 9%.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Is the breakthrough path all in AI? Chain pharmacies are facing a wave of closures and an era of low profits.
① In 2024, particularly in the second half of the year, chain pharmacies will face a large-scale wave of closures, and leading chain pharmacies will generally enter a low-profit era. ② AI is also being assigned higher expectations in helping pharmacies reduce costs and increase efficiency. ③ Publicly available large models, due to a lack of support from vertical domain data, are still insufficient to support the actual Business Operation of pharmacies.
Asymchem Laboratories (06821.HK) held a Board of Directors meeting on March 28 to consider and approve the annual performance.
Gelonghui reported on March 14th that Asymchem Laboratories (06821.HK) announced that the Board of Directors meeting will be held on March 28, 2025 (Friday) to consider and approve the performance of the company and its subsidiaries for the year ending December 31, 2024, and its release, as well as to consider the proposal to distribute a final dividend (if any).